
    
      This exploratory trial is to compare the efficacy of secondary cytoreductive surgery followed
      by chemotherapy and Niraparib maintenance, versus chemotherapy alone followed by Niraparib
      maintenance in patients with platinum-sensitive secondary recurrent ovarian cancer who never
      received secondary cytoreduction when recurrent.
    
  